INmune Bio Inc. to Announce Top Line Results from MINDFuL Phase 2 Trial in Early Alzheimer's on Monday, June 30th
MWN-AI** Summary
INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company focused on inflammation and immunology, is set to announce the top-line results from its Phase 2 MINDFuL trial for early Alzheimer's Disease on June 30, 2025. The conference call will commence at 8:00 AM EDT, where executives will discuss the findings from this pivotal trial targeting neuroinflammation in patients with Mild Cognitive Impairment (MCI) and early Alzheimer’s.
The MINDFuL trial (NCT05318976) is a randomized, blinded study assessing the efficacy of XPro™, a next-generation TNF inhibitor, developed to selectively neutralize soluble TNF without affecting transmembrane TNF. This drug is administered via weekly subcutaneous injections and aims to improve cognitive functions through the reduction of neuroinflammation, measured by specific biomarkers.
Participants in the trial exhibit elevated levels of inflammation, determined by biomarkers such as CRP, HbA1c, ESR, or the ApoE4 allele, and are assigned to either XPro™ or a placebo group (2:1 ratio) for six months. The results from these assessments will shed light on the potential of XPro™ in treating early-stage Alzheimer’s, a critical area given the increasing global prevalence of this neurodegenerative disease.
The company will provide a comprehensive update following the results call, with a transcript expected within 24 hours and a replay available until July 30, 2025. INmune Bio is dedicated to leveraging its research into targeted therapies for chronic inflammation and cancer through its various product platforms, including the Natural Killer Cell Priming Platform and the CORDStrom™ platform focused on stem cell therapies.
Investors and interested parties are encouraged to attend the conference call for insights on INmune Bio’s advancements in Alzheimer’s research and its broader therapeutic initiatives.
MWN-AI** Analysis
As INmune Bio Inc. (NASDAQ: INMB) prepares to announce the top-line results from its MINDFuL Phase 2 trial for early Alzheimer's Disease on June 30, 2025, investors should closely monitor the implications of these results for the company's future. The MINDFuL trial focuses on patients with mild cognitive impairment (MCI) and early-stage Alzheimer's, utilizing XPro™, a next-generation tumor necrosis factor (TNF) inhibitor designed to reduce neuroinflammation linked to cognitive decline.
Historically, results from clinical trials in the biotech sector can lead to significant volatility in stock prices. A positive outcome could immensely bolster INmune Bio's market position by validating the effectiveness of XPro™ and attracting potential partnerships or investments. Conversely, unfavorable results could lead to a sharp decline in stock value as market sentiment turns negative.
Investors should pay attention to various indicators in the upcoming call, including detailed cognitive endpoints assessed in the trial, which are expected to clarify the drug's efficacy. If the data suggest meaningful improvements, it could enhance the stock's attractiveness, signaling robust potential in the neuroscience therapeutics space. Given the immense need for effective Alzheimer's treatments, a successful trial may also place INmune Bio in a favorable bargaining position regarding licensing agreements or collaborations.
On the earnings call, analysts will look for insights on management’s regulatory strategy and next steps following the trial results. As revealed in INmune's prior communications, navigating the complexities of clinical trials presents significant risks and uncertainty; investors should calibrate their expectations accordingly.
In conclusion, prudent investors should take a cautious approach, closely monitoring the outcomes of the MINDFuL trial while considering the high-risk, high-reward nature of biopharmaceutical investments, particularly in the neurodegenerative disease domain.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Company to host a conference call to discuss results at 8:00am EDT on June 30, 2025
Boca Raton, Florida, June 26, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, will host a conference call on Monday, June 30 beginning at 8:00am EDT to present top line data from the Phase 2 MINDFuL trial in early Alzheimer’s Disease.
MINDFuL Results Call Information:
To participate in this event, dial approximately at least 10 minutes before the beginning of the call or use the webcast link below. Please ask for the INmune Bio MINDFuL Conference Call when reaching the operator.
Date: June 30, 2025
Time: 8:00 AM Eastern Time
Participant Dial-in: +1-800-267-6316 Participant Dial-in (international): +1-203-518-9783
Conference ID: INMUNE
**NOTE: THIS CONFERENCE ID WILL BE REQUIRED FOR ENTRY
To join by webcast link please click here or copy and past the link below into your browser:
https://viavid.webcasts.com/starthere.jsp?ei=1725659&tp_key=5cf89734df
A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through July 30, 2025 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering pin no. 11159260.
About MINDFuL (NCT05318976)
The MINDFuL trial is an international, blinded, randomized Phase 2 trial in patients with Early AD with biomarkers of elevated neuroinflammation. Early AD includes patients with MCI (mild cognitive impairment) and mild AD. Patients must have at least one of four biomarkers of inflammation – elevated CRP, HgbA1c, ESR or ApoE4 allele. Patients receive either XPro™ or placebo (2:1 ratio) for 6 months. The cognitive endpoints are EMACC and CDR. XPro™ is given as a once-a-week subcutaneous injection. For more information on the MINDFuL clinical trial please visit www.clinicaltrials.gov or www.inmunebio.com
About XPro™
XPro™ is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro™ could have potential substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website .
About INmune Bio Inc.
INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom ™ , is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio’s product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer. To learn more, please visit www.inmunebio.com .
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. CORDstrom™, XPro1595 (XPro™), and INKmune®™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Company Contact:
David Moss
Chief Financial Officer
(561) 710-0512
info@inmunebio.com
Daniel Carlson
Head of Investor Relations
(415) 509-4590
dcarlson@inmunebio.com
FAQ**
Can you provide more insights into the top line data from the Phase 2 MINDFuL trial for early Alzheimer's Disease that will be presented during the call, and what implications they may have for the future of INmune Bio Inc. INMB's product pipeline?
How does the mechanism of action for XPro™ compare to other existing TNF inhibitors, and what specific outcomes are you hoping to achieve that may demonstrate its superiority during the conference call on June 30, 2025?
Are there any plans for expanding the clinical trials of INmune Bio Inc. INMB's product candidates beyond early Alzheimer's Disease, particularly targeting other neuroinflammatory diseases, and what data can we expect moving forward?
In light of the potential for substantial beneficial effects of XPro™ in patients with neurologic disease, what are the expected next steps for INmune Bio Inc. INMB following the MINDFuL trial results and how will you ensure continued funding for these initiatives?
**MWN-AI FAQ is based on asking OpenAI questions about INmune Bio Inc. (NASDAQ: INMB).
NASDAQ: INMB
INMB Trading
-5.44% G/L:
$1.565 Last:
646,918 Volume:
$1.66 Open:
